Agilent pd-l1 ihc 28-8 pharmdx receives eu ivdr certification as a companion diagnostic test for non-small cell lung cancer and melanoma indications

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced its pd-l1 ihc 28-8 pharmdx kit has received two new companion diagnostic indications approvals under eu ivdr1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (nsclc) and previously untreated advanced melanoma patients. these two new indications bring the total indications launched in europe for pd-l1 ihc 28-8 pharmdx to nine. pd-l1 ihc 28-8 pharmdx is approved for exclusiv.
A Ratings Summary
A Quant Ranking